Spots Global Cancer Trial Database for mibc
Every month we try and update this database with for mibc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03397394 | Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | NCT04630730 | Bladder Cancer | Recombinant int... Atezolizumab Cisplatin Gemcitabine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Clinical Performance Evaluation of the C2i Test | NCT05860543 | Muscle Invasive... | C2i-WGS-MRD Tes... | 22 Years - | University of Texas Southwestern Medical Center | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging | NCT02203136 | Bladder Cancer | Tissue Biopsy Magnetic Resona... | - | M.D. Anderson Cancer Center | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | NCT03636256 | Bladder Cancer Urothelial Carc... Urinary Bladder... Urinary Bladder... Urogenital Neop... Urologic Neopla... Urologic Cancer Malignant Tumor... Cancer of the B... | NanoDoce (direc... NanoDoce (intra... Institutional S... NanoDoce (intra... | 18 Years - | NanOlogy, LLC | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | NCT05483868 | Non-muscle-inva... Muscle-Invasive... | AU-011 AU-011 in Combi... AU-011 in Combi... | 18 Years - | Aura Biosciences | |
| Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | NCT04630730 | Bladder Cancer | Recombinant int... Atezolizumab Cisplatin Gemcitabine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging | NCT02203136 | Bladder Cancer | Tissue Biopsy Magnetic Resona... | - | M.D. Anderson Cancer Center | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Clinical Performance Evaluation of the C2i Test | NCT05860543 | Muscle Invasive... | C2i-WGS-MRD Tes... | 22 Years - | University of Texas Southwestern Medical Center | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
